< content="width=device-width, initial-scale=1.0"> Gregory S. Hageman | School of Medicine
Gregory S. Hageman

Gregory S. Hageman, PhD

Languages spoken: English

Academic Information

Departments Primary -

Academic Office Information

Gregory.Hageman@hsc.utah.edu

Research Interests

  • The Biology, Genetics and Development of Diagnostic and Therapeutic Modalities for the Treatment of Age-Related Macular Degeneration and its Co-Segregating Diseases

Gregory S. Hageman, PhD, is the John A. Moran Presidential Professor of Ophthalmology and Visual Sciences at the University of Utah John A. Moran Eye Center. He serves as the Executive Director of Moran’s Steele Center for Translational Medicine (SCTM), which was created to exploit a repository of patient and tissue resources and foster a robust understanding of age-related macular degeneration (AMD) biology to discover pathways, identify and validate therapeutic targets, and develop therapies for early-stage AMD.

Dr. Hageman is a graduate of the University of Southern California, where he conducted his undergraduate and graduate studies in biology and marine biology. Prior to relocating to Utah, he served as the Iowa Entrepreneurial Professor and Director of the Cell Biology and Functional Genomics Laboratory at the University of Iowa. He has also held appointments as Professor Universite Descartes Paris and Associate Faculty in the Center for the Study of Macular Degeneration, University of California, Santa Barbara, and has received honorary professorships at Queen’s University, Belfast, U.K., and the Shandong Eye Institute, Qingdao, China.

Dr. Hageman’s primary research interest over the past 30 years has been directed toward the genetics and biology of AMD, a leading cause of irreversible worldwide blindness. Dr. Hageman and his colleagues discovered that a specific common haplotype of the complement regulator, Complement Factor H (CFH), in combination with variations in another complement regulator, Complement Factor B (CFB), account for greater than 50% of risk for AMD in Caucasian populations. More recently, he has generated strong ocular and systemic evidence that AMD is at least two biologically distinct diseases. Dr. Hageman garnered contiguous funding from the National Eye Institute/National Institutes of Health for more than 25 years. He was the principal investigator of a $14.7M R24 translational award supported by NIH/NEI and involving colleagues from 12 participating national and international institutions.

Dr. Hageman has been an active member of various professional and honorary organizations and numerous national and international advisory boards, panels, and review committees. He has briefed the U.S. Congress on three occasions and presented a number of plenary and named lectureships, including the Ashton Eponymous, Broadhurst Foundation, Davson, LuEsther Mertz, Bradley R. Straatsma, Allergan Foundation, F. Phinizy Calhoun Jr., Joseph M. Bryan, Walter R. Stafford, James A. Craig, the Robert B. Barlow Distinguished, Harold Gifford Jr., George E. Smelser, and the Jonathan Bok Memorial lectures. He has received the Trustee Award from the Foundation Fighting Blindness, an Alcon Research Institute Award, the Fondazione G.B. Bietti Award, the Lew R. Wasserman Merit Award, the Olga Keith Wiess Scholar, and Senior Investigator Awards from Research to Prevent Blindness, the Roger Johnson Prize for Macular Degeneration Research, the Lighthouse International Madame Georgette Pisart Vision Award, and the Macula of Paris Prix de la Recherche for his contributions to AMD research. He has been named to The Ophthalmologist Power List on three occasions.

Dr. Hageman and colleagues founded Voyant Biotherapeutics, a biotechnology company that is partnering with the Moran Eye Center to efficiently capitalize the commercialization of scientific discoveries made within the SCTM. Voyant mediated a unique collaborative partnership between the SCTM, Voyant, and Allergan in December 2012 to identify targets for gene-directed AMD. Most recently, Voyant closed a Series A financing round to expedite the pace of development of novel AMD therapeutics; a Phase I trial of one therapeutic is anticipated in 2021. Dr. Hageman serves as the CSO and a Board Member of Voyant.

Greg and his wife, Jill, have been married for 40 years. They have two wonderful children, Courtney and Nicholas, who currently live in Oregon and Iowa.

Education History

Doctoral Training University of Southern California
 PhD
University of Southern California
 BS

Selected Publications

Journal Article

  1. Gorusupudi A, Liu A, Hageman GS, Bernstein PS (2016). Associations of human retinal very long-chain polyunsaturated fatty acids with dietary lipid biomarkers. J Lipid Res, 57(3), 499-508.
  2. Keenan TD, Toso M, Pappas C, Nichols L, Bishop PN, Hageman GS (2015). Assessment of Proteins Associated With Complement Activation and Inflammation in Maculae of Human Donors Homozygous Risk at Chromosome 1 CFH-to-F13B. Invest Ophthalmol Vis Sci, 56(8), 4870-9.
  3. Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2015). Fundus autofluorescence characteristics of nascent geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci, 56(3), 1546-52.
  4. Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2014). Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology, 121(12), 2415-22.
  5. Finger RP, Wu Z, Luu CD, Kearney F, Ayton LN, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2014). Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology, 121(6), 1252-6.

Patent

  1. Hageman GS, Smith RJ (2011). Methods and Reagents for Treatment and Diagnosis of Age-Related Macular Degeneration (CFH). U.S. Patent No. US 7867727 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Hageman GS (2010). Assessing Susceptibility to Vascular Disorders (ParAllele). U.S. Patent No. US20100324154 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Hageman GS (2010). Methods for Treatment of Age-related Macular Degeneration. U.S. Patent No. US 7745389 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Hageman GS, Mullins RF (2010). Diagnostics and Therapeutics for Macular Degeneration-Related Disorders. U.S. Patent No. US7682804 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Hageman GS (2010). RCA Locus Analysis to Assess Susceptibility to AMD and MPGNII. U.S. Patent No. WO2009059321 A3. Washington, D.C.:U.S. Patent and Trademark Office.
  6. Hageman GS (2009). Genes and Polymorphisms Associated with AMD (ParAllele). U.S. Patent No. WO/2009/059318. Washington, D.C.:U.S. Patent and Trademark Office.
  7. Hageman GS (2009). Predicting AMD with SNPs Within or Near C2, Factor B, PLEKHA1, HTRA1, PRELP, or LOC387715 (ParAllele). U.S. Patent No. WO2009059317 A3. Washington, D.C.:U.S. Patent and Trademark Office.
  8. Hageman GS, Mullins RF (2009). Diagnostics and Therapeutics for Drusen Associated Ocular Disorders (Drusen-associated Markers). U.S. Patent No. CA2363503. Washington, D.C.:U.S. Patent and Trademark Office.
  9. Hageman GS, Meri S (2008). Binding of Complement Factor H to C-Reactive Protein (CFH-CRP Binding). U.S. Patent No. EP2008101 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  10. Allikmets RL, Hageman GS, Dean MC, Gold AM (2008). Variants In Complement Regulatory Genes Predict Age-Related Macular Degeneration (CFB/C2 Diagnostics). U.S. Patent No. WO2007120975 A8. Washington, D.C.:U.S. Patent and Trademark Office.
  11. Hageman GS (2008). Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration (CFHR1/R3 Deletion). U.S. Patent No. WO2008008986 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  12. Hageman GS, Kuehn MH (2007). Nuclei Acids Encoding Interphotoreceptor Matrix Proteins (IPM). U.S. Patent No. US7312050. Washington, D.C.:U.S. Patent and Trademark Office.
  13. Hageman GS (2007). Biomarkers Associated With Age-Related Macular Degeneration (DIGE & MALDI Biomarkers). U.S. Patent No. WO2007032876 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  14. Hageman, GS (2006). Diagnostics and Therapeutics for Macular Degeneration (AAA to AMD; EDP/CRP/C3/C5). U.S. Patent No. US7108982. Washington, D.C.:U.S. Patent and Trademark Office.
  15. Hageman GS, Mullins RF (2006). Diagnostics and Therapeutics for Macular Degeneration-Related Disorders (Autoantibodies). U.S. Patent No. US7011952. Washington, D.C.:U.S. Patent and Trademark Office.
  16. Hageman GS (2001). Diagnostics and Therapeutics for Arterial Wall Disruptive Disorders (AMD to AAA). U.S. Patent No. WO2001002866 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  17. Neitz J, Anderson DH, Johnson LJ, Hageman GS (1995). Camouflage Materials for Reducing Visual Detection by Deer and Other Dichromatic Animals. U.S. Patent No. US5292509. Washington, D.C.:U.S. Patent and Trademark Office.
  18. Hageman GS (1994). Method for the Disinsertion of Vitreous Body by an Enzyme which Disrupts or Degrades Chondroitin Sulfate Proteoglycan. U.S. Patent No. US5741692. Washington, D.C.:U.S. Patent and Trademark Office.